论文部分内容阅读
目的:探讨聚糖蛋白3在原发性肝癌病理诊断中的意义。方法:选取2015年1月-2016年1月在我愿接受治疗的原发性肝癌患者30例作为实验组,与此同时,选取30名健康人作为研究的正常组。两组研究对象采用生物素-链霉素和素双抗体夹心酶联免疫吸附实验方法测定患者血清中的聚糖蛋白3的含量。结果:实验组患者的聚糖蛋白3的含量显著高于正常组,与此同时,若根据阳性检测率标准,实验组患者的阳性检测率为83.33%,正常组健康者的检出率仅为3.33%。两组具有显著性差异,P<0.05,具有统计学意义。结论:在临床中采用测定聚糖蛋白3的含量能够及时的对肝癌患者进行筛选,有利于肝癌早期的发现与治疗。
Objective: To investigate the significance of gp3 in the pathological diagnosis of primary liver cancer. Methods: From January 2015 to January 2016, 30 patients with primary hepatocellular carcinoma I would like to receive treatment were selected as the experimental group, while 30 healthy individuals were selected as the normal group. Two groups of patients using biotin-streptavidin and superantigen antibody sandwich enzyme-linked immunosorbent assay to determine the serum levels of glycoprotein 3. Results: The content of gp3 in the experimental group was significantly higher than that in the normal group. At the same time, if the positive detection rate was 83.33% in the experimental group, the detection rate of the normal group was only 3.33%. There was a significant difference between the two groups, P <0.05, with statistical significance. Conclusion: The clinical application of the determination of glycoprotein 3 can timely screening of patients with liver cancer is conducive to the early detection and treatment of liver cancer.